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were excluded. For this study, pts were randomly assigned either to a model deriva- 
tion(n=750) or validation(n=751) group. Logistic regression was used to identify those 
patient characteristics that best predicted P-blocker utilization in the derivation group. 
Modal goodness-of-fit was assessed. and the model validated. 
Results: The mean age of the population was 67215 yrs, 55% were women, 25% were 
African American and 69% had coronary altery disease. Assessment of left ventricular 
funcbon(LVF) was documented in 90% of pts. ACE-I therapy was prescribed in 76% and 
P-blockers were prescribed in 50% overall and in 59% of pts with systolic HF. In the deri- 
vation model, characteristics associated with receiving P_blockers included documented 
LVF(p<O.Ol). systolic dysfunction(pcO.Ol), coronary artery disease(p<O.Ol), inSurance 
type(p<O.Ol), and hypertenslon(p=03). Trends were noted for younger age(pc0.01) and 
ACE-I therapy(p=O.Ol), In the final multivariate model, coronary artery disease, docu- 
mented LVF, hypertension, and insurance type were significant predictors of P-blocker 
therapy Area under the ROC curve for both the final model and the derwation sample 
was 0.67. 
Conclusions: Although not optimal, eblocker utilization in patients with HF is higher 
than previously reported. Important predictors of eblocker prescription I” this sample of 
managed care pts are documented LV function and coronary artery disease. Strategies 
to increase &blocker therapy should be developed. 
long-term reductions in LV volumes, in contrast to ongoing ACE-I alone. Despite a 
change in therapy, C patients did not experience more adverse events and a similar 
number of patients completed the study. Therefore, Carvedilol might be regarded as pos- 
sible alternative to ACE-I in mild CHF patients. 
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Background: The Influence of gender on treatment and suwival in congestive heart fall- 
ore (HF) is understudied. Here, post-hoc analyses of primary endpoints of mortality (M) 
and combined mortality/morbidity and secondary endpoint of non-fatal morbidity (NFM) 
examined differences in men. women and postmenopausal women (age _> 55years) in 
the Valsartan Hear? Failure Trial (Val-HeFT). Methods: 5010 HF patients (4007 men and 
1003 women) were randomized to either valsartan (V) or placebo (P) in addition to pre- 
scribed HF therapy. Outcomes in pooled populations (V+P) and treatment effects (V vs 
P) were evaluated using Cox regression analysis. 
Results: Regardless of subgrouping by age above or below 55, the pooled population of 
women had lower M than men (16.3% vs 20.4%, p=O.O02) but women. especially post- 
menopausal women (n=791) had higher NFM (subgroup: Z55years - 21.1% vs 17.4%, 
p=O.O35). However, women with coronary heart disease, regardless of age above or 
below 55, had similar M as men (20.5% vs 22.6%, ~~0.187) while the higher rate of NFM 
remained (24.5% vs 16.3%, p<O.OOl). Similar results were seen wth diabetes co-mor- 
bidity. The use of background therapy wth ACE inhibitors, digoxin, O-blockers and diuret- 
ICS was similar between women and men, and none of these therapies had an Impact on 
gender differences within the pooled population. Between-treatment analyses for V vs P 
within males, females and post-menopausal females demonstrated a favorable effect or 
trend on combined mortality/morbidity endpoint in all three subgroups. 
Background: Nesiritide (Natreco@ Scios Inc., Sunnyvale, CA) is a recombinant form of 
human B-type natriuretic peptide, that has been shown to be beneficial in patients with 
decompensated congestive heart failure. This study evaluated the effects of nesiritide on 
coronary blood flow (CBF) and myocardial oxygen extraction. 
Methods: Patients referred for cardiac catheterization were enrolled. Patients who had 
baseline SBP < 95 mm Hg, were on vasopressors. and had received nitroglycerin or cal- 
cium blockers within the previous 24 hours were excluded. After diagnostic catheteriza- 
tion and full heparinization, a O.OlCinch Doppler FloWire was positioned in the proximal 
portion of an unobstructed coronary artery to measure average peak velocity (APV). 
Right heart catheterization and simultaneous blood gas sampling from the coronary sinus 
and aorta were performed at baseline and after a 30.min IV infusion of nesiritide (2mcg/ 
kg bolus and 0.01mcgikglmin). Quantitative coronary angiography was performed at 
baseline, lBmin, and 30-min. CBF=(coronary altery area)(APV)(0.3). Coronary resis- 
tance=mean arterial pressure/CBF. 
Results: Ten patients were enrolled. The mean age was 56*12 years (range 43-60). 
Three were female. Mean left ventricular ejection fraction was 46+20% (range 20.70%). 
During nesiritide infusion, pulmonary capillary wedge pressure decreased 46% 
(p=O.O02). mean pulmonary artery pressure decreased 19% (p=O.O3). systemic vascular 
resistance decreased 6% (p&22), and mean arterial pressure decreased 11% 
(p=O.O07). There was no significant change in cardiac output. Coronary artery APV 
increased from 21+6 cm/s at baseltne to 24i7 cm/s at 5 min (p=O.Ol), returning to base- 
line at 15 and 30 minutes. Coronary artery diameter increased 15% at 15. and 30.min 
(p=O.O07). CBF increased 33% at 15 min (p=O.O3) and 32% at 30 min (p=O.O7). Coronary 
resistance decreased 29% at 15 min (p=O.O2) and 29% at 30 min (p=O.O4). Myocardial 
oxygen extraction decreased 5% at 30 min (p=O.13). 
Conclusion: Nesiritide exerts coronary vasodilator effects, in both the epicardial conduc- 
tance and resistance arteries. There is a trend toward decreased myocardial oxygen 
extraction during nesiritide infusion. 
1184-75 Effect of Nonsurgical Heart Failure Therapies on 
Functional Mitral Regurgitation: A Meta-Analysis 
Conclusions: In Val-HeFT. the female gender was associated with lower M but a higher 
rate of NFM, especially for postmenopausal women. Primary HF etiology of coronary 
heart disease or a history of diabetes dilutes the gender benefit for M independent of 
age. These findings suggest that serious attention should be paid to postmenopausal 
women and those with comorbidities. Future studies should continue to enroll more 
female patients. Gender differences in HF M and NFM must be seriously considered both 
I” clinical practice and in the design of future HF studies. 
Madhavi Kadivala Martin Fewerman. Jason M. Lazar, Winthrop-University Hospital, 
Mineola, NY 
Background: Functional mitral regurgitation (MR) is a common echocardiographic find- 
ing in patients with congestive heart failure (CHF) and its presence and magnitude are 
associated with an adverse prognosis. The objective of this systematic overview using 
meta-analysis was to assess effects of hearl failure therapies on functional MR. 
Methods: Studies ware retrieved using medline and ovid (key words: mitral regurgitation, 
heart failure treatment). All clinical trials published I” English from 1965 to the present 
date ware included. Eighteen previously published studies met the criterion for our analy- 
sis. In these studies Doppler echocardiography was used to assess the degree of MR 
before and at least 1 month after the initiation of ace inhibitors (ace-l), beta-blockers (bb) 
or pacing in patients with CHF. Standardized effect size of reduction in MR was calcu- 
lated using Cohen’s ‘d’ for each study. Random effects model was used for the meta- 
analysis. Pearson’s correlation analysis was performed to assess the relation between 
various echo parameters and MR. 
Results: Functional MR was assessed in a total of 594 patients in 18 trials (4 ace-l, 4 bb 
and 10 pacing). By unweighted analysis, ace-l reduced MR by 59i 20% With the major- 
ity of patients on background ace-l therapy. bb reduced MR by 55i 24%. Pacing reduced 
MR by 26+ 15%, when added to optimal medical therapy. In a random effects model, the 
effect size (d) of MR reduction by ace-l and bb was large, d = - 1.04+ 0.36 (95% Cl - 
1.75, -0.34) and -i.l& 0.36 (95% Cl -1.86;0.46) respectively. Pacing therapy had a 
moderate effect on reduction of MR ( d= -0.59+ 0.06 (95% Cl -0.76, -0.43)). Pearson’s 
correlation analysis of effect sizes showed a trend toward reduction in MR correlating 
with an improvemerit in LV ejection fraction (r= -0.38, p ~0.15) and decrease in LV end 
diastolic diameter (r= 0.46, p= 0.11). 
Conclusion: In petlents with CHF and functional MR, ace-l and bb reduce MR to a large 
extent. Pacmg including cardiac resynchronization therapy reduced MR to a moderate 
extent. Further studies are required to understand the mechanism of these therapies on 
MR. 
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Background: In chronic heart failure (CHF), the effect of Pblockade on mortality. mor- 
bidity and cardtac remodeling have always been evaluated in addition to ACE-I. It is 
unknown whether the combination is mandatory or whether in terms of remodeling ACE- 
I can successfully be replaced by eblockade. CARMEN compared the effect on remod- 
eling of the ACE-I Enalapr~l (E) against Carvedilol (C), a combined pl .@2 -blocker with 
additional al-receptor blockade and anti-oxidant properties. 
Methods: A parallel-group, 3.arm. double-dummy, multi-center study was conducted in 
13 European countries. Patients ware randomized to C &E. C and E treatment, uptitrated 
on C to 25mg BID target dose and/or E to 1Omg BID target dose, and continued for 16 
months. Earlier ACE-I and P-blocking treatment was stopped prior to randomization. In 
the C&E arm, C was uptitrated first. Effects of left ventricular (LV) remodeling were 
assessed by transthoracic echocardiography (biplane) at baseline. months 6, 12 and 16 
at a central core laboratory 
Results: 572 mild CHF patients, mean age 62 years, 61% males, were randomized. Of 
these, 65% (N=374) had been on ACE-I treatment prior to the study start, whereas only 
6% were on p-blockade. A subgroup analysis of the primary endpoint in former ACE-I 
users showed that LV end-systolic volume index was reduced at month 16 by 4.7 ml& 
(p=O.O06) I” the C group (n=l03) and by 6.0 ml/m2 (p=O.OOi) in the C&E group (n=ll4) 
from baseline. In contrast, in the E group (n=lOl) it increased by 0.6 ml/m2 (ns). The 
overall safety and tolerability profiles were comparable. In groups C&E, C and E adverse 
events occurred in 76%,75% and 74 %, respectively, whereas similar percentages of 
patients completed treatment (74%,70% and 72% respectively). 
Conclusion: Combination therapy (C&E) gave best results. However, replacement of 
ACE-I with C also resulted in significant reversal of cardiac remodeling with sustained, 
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Background: HMG-CoA reductase inhibitors (statins) are one of the most potent modifi- 
ers of coronary artery disease (CAD) natural history. PrescrIption rates and efficacy of 
statins have not been explicitly studied in patients (pts) with left ventricular dysfunction 
(LVD. Ejection Fraction [EFr40%). Potentially, statins could adversely effect LVD pts 
due to decreased hepatic blood flow or pharmacologic interaction (e.g with amiodarone). 
